Here’s the introduction to their piece published July 12 2020.
Whenever I speak with her, Mary Cosimano, the director of guide/facilitator services at Johns Hopkins Center for Psychedelic and Consciousness Research, mentions the women in the chamber and the cup. My experience struck a chord. For me, the women in the chamber have become a transcendent metaphor for emotional healing.
“I’ve thought about having a necklace made, with the cup, as a momento,” she said the last time I saw her at a conference. “Have you thought about it?”
Prior to their 1971 prohibition, psilocybin and LSD were administered to approximately 40,000 patients, among them people with terminal cancer, alcoholics and those suffering from depression and obsessive-compulsive disorder. The results of the early clinical studies were promising, and more recent research has been as well.
The treatment certainly helped me. Eight years after my sessions, researchers continue to prove the same point again and again in an ongoing effort to turn psychedelic drug therapy into FDA-sanctioned medical treatment. This can’t happen soon enough.
“Psychopharmacology as a field had stalled. Many patients don’t respond to conventional treatment with SSRIs,” says Charles Grob, M.D., professor of psychiatry and biobehavioral Sciences at Harbor-UCLA Medical Center, and the first modern clinical researcher to treat advanced-stage cancer patients suffering from depression and anxiety with psychedelics.